Latest Breaking News On - Professor maria victoria mateos - Page 1 : vimarsana.com

Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Northern irelandUnited kingdomUnited statesCastillay leópElcin barker ergunMaria victoria mateosEuropean hematology associationKaryopharm therapeutics incEuropean commissionStemline therapeutics incMenarini groupUniversity hospital salamancaWorld health organizationStemline therapeuticsProfessor maria victoria mateosMeeting presentation

Menarini Industrie Farmaceutiche Riunite: Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

Data demonstrate a significant 71% reduction in risk of disease progression or death in selinexor + bortezomib + dexamethasone (SVd) arm versus bortezomib + dexamethasone (Vd) arm in PI-naïve

United statesUnited kingdomNorthern irelandCastillay leópMecklenburg vorpommernElcin barker ergunMaria victoria mateosStefan klotterMenarini groupStemline therapeutics incKaryopharm therapeutics incEuropean hematology associationEuropean commissionWorld health organizationUniversity hospital salamancaStemline therapeutics